Because it already exists naturally in the body, supporting its levels may help encourage healthier collagen production, improved skin resilience, and better repair over time
Although dual and triagonist medications have so far exhibited side effects comparable to those of GLP- 1 receptor monoagonists in human trials, these preclinical findings imply that GIP receptor agonism may be the secret to obtaining the weight loss advantages of incretin agonism with less severe side effects
Direct human clinical trial evidence
Soltaninassab SR, Sekhar KR, Meredith MJ, Freeman ML (2000) Multi-faceted regulation of gamma-glutamylcysteine synthetase
Read Guide Melanotan-1 vs Melanotan-2: Key Differences & Regulatory Status Melanotan-1 and Melanotan-2 are both alpha-MSH analogues studied in the melanocortin pathway, but they differ in receptor selectivity and, importantly, in regulatory status
Balancing weight and muscle loss in GLP1 receptor agonist therapy
